21860-24-2

Upstream product

• 25125-21-7 4-(hydroxymethyl)cyclopentene 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Downstream Products

• 197227-61-5 (S)-4-benzyl-3-[(2S,3R)-4-cyclopent-3-enyl-3-hydroxy-2-methylbutanoyl]-oxazolidin-2-one 
• 423116-50-1 9-(tert-butyl-dimethyl-silanyloxy)-7-[5-(tert-butyl-diphenyl-silanyloxy)-2-methoxy-1,3-dimethyl-pent-3-enyl]-10,14-dimethyl-6,16-dioxa-bicyclo[13.3.1]nonadeca-3,10,12-triene-5,17-dione 
• 910223-55-1 4-cyclopent-3-enyl-2-diazo-3-oxo-butyric acid 2-oxo-1-phenyl-2-pyrrolidin-1-yl-ethyl ester 
• 910223-57-3 2-oxo-1,2,3,3a,4,6a-hexahydro-pentalene-1-carboxylic acid 2-oxo-1-phenyl-2-pyrrolidin-1-yl-ethyl ester 

Relevant academic research and scientific papers

Desymmetrization of cyclic olefins via asymmetric Heck reaction and hydroarylation

An asymmetric Heck reaction allows desymmetrization of substituted cyclic olefins in high dr and ee. A bisphosphine oxide is uniquely stereoselective for this purpose. Desymmetrization of bicyclic olefins via hydroarylation can also be realized in high ee.

A novel synthesis of bicyclo[3.3.0]octane ring system via a desymmetric C-H insertion reaction

An optically active bicyclo[3.3.0]octane ring was synthesized by an intramolecular C-H insertion reaction. Upon treatment with a catalytic amount of Rh2(S-DOSP)4, a chiral-auxiliary-containing diazoester underwent a C-H insertion reaction to give the desired bicyclo[3.3.0]octane system. Georg Thieme Verlag Stuttgart.

NOVEL METHODS AND COMPOSITIONS FOR ALLEVIATING PAIN

The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic α-adrenergic receptor in the absence of α-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic α-adrenergic receptor can be, for example, the α-2B receptor.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.